JYNT Quote, Financials, Valuation and Earnings

CVS Health Corp. has a net margin of 2.17% compared to The Joint Corp. (United States)'s net margin of 2.77%. The Joint Corp. (United States)'s return on equity of -1.38% beat CVS Health Corp.'s return on equity of 2.28%.

The Joint Corp. (United States) has a consensus price target of $10.67, signalling upside risk potential of 16.2%. On the other hand CVS Health Corp. has an analysts' consensus of $96.50 which suggests that it could grow by 23.7%. Given that CVS Health Corp. has higher upside potential than The Joint Corp. (United States), analysts believe CVS Health Corp. is more attractive than The Joint Corp. (United States).

The Joint Corp. (United States) has a beta of 1.349, which suggesting that the stock is 34.866% more volatile than S&P 500. In comparison CVS Health Corp. has a beta of 0.496, suggesting its less volatile than the S&P 500 by 50.368%.

The Joint Corp. (United States) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health Corp. offers a yield of 3.41% to investors and pays a quarterly dividend of $0.67 per share. The Joint Corp. (United States) pays -- of its earnings as a dividend. CVS Health Corp. pays out 191.23% of its earnings as a dividend.

The Joint Corp. (United States) quarterly revenues are $13.4M, which are smaller than CVS Health Corp. quarterly revenues of $105.7B. The Joint Corp. (United States)'s net income of $290.4K is lower than CVS Health Corp.'s net income of $2.9B. Notably, The Joint Corp. (United States)'s price-to-earnings ratio is 79.62x while CVS Health Corp.'s PE ratio is 56.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint Corp. (United States) is 2.57x versus 0.25x for CVS Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Enhabit, Inc. has a net margin of 2.17% compared to The Joint Corp. (United States)'s net margin of 4.4%. The Joint Corp. (United States)'s return on equity of -1.38% beat Enhabit, Inc.'s return on equity of -1.74%.

The Joint Corp. (United States) has a consensus price target of $10.67, signalling upside risk potential of 16.2%. On the other hand Enhabit, Inc. has an analysts' consensus of $13.44 which suggests that it could fall by -1.18%. Given that The Joint Corp. (United States) has higher upside potential than Enhabit, Inc., analysts believe The Joint Corp. (United States) is more attractive than Enhabit, Inc..

The Joint Corp. (United States) has a beta of 1.349, which suggesting that the stock is 34.866% more volatile than S&P 500. In comparison Enhabit, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Joint Corp. (United States) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enhabit, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint Corp. (United States) pays -- of its earnings as a dividend. Enhabit, Inc. pays out -- of its earnings as a dividend.

The Joint Corp. (United States) quarterly revenues are $13.4M, which are smaller than Enhabit, Inc. quarterly revenues of $263.6M. The Joint Corp. (United States)'s net income of $290.4K is lower than Enhabit, Inc.'s net income of $11.6M. Notably, The Joint Corp. (United States)'s price-to-earnings ratio is 79.62x while Enhabit, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint Corp. (United States) is 2.57x versus 0.66x for Enhabit, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

First Physicians Capital Group, Inc. has a net margin of 2.17% compared to The Joint Corp. (United States)'s net margin of --. The Joint Corp. (United States)'s return on equity of -1.38% beat First Physicians Capital Group, Inc.'s return on equity of --.

The Joint Corp. (United States) has a consensus price target of $10.67, signalling upside risk potential of 16.2%. On the other hand First Physicians Capital Group, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that The Joint Corp. (United States) has higher upside potential than First Physicians Capital Group, Inc., analysts believe The Joint Corp. (United States) is more attractive than First Physicians Capital Group, Inc..

The Joint Corp. (United States) has a beta of 1.349, which suggesting that the stock is 34.866% more volatile than S&P 500. In comparison First Physicians Capital Group, Inc. has a beta of 0.522, suggesting its less volatile than the S&P 500 by 47.813%.

The Joint Corp. (United States) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint Corp. (United States) pays -- of its earnings as a dividend. First Physicians Capital Group, Inc. pays out -- of its earnings as a dividend.

The Joint Corp. (United States) quarterly revenues are $13.4M, which are larger than First Physicians Capital Group, Inc. quarterly revenues of --. The Joint Corp. (United States)'s net income of $290.4K is higher than First Physicians Capital Group, Inc.'s net income of --. Notably, The Joint Corp. (United States)'s price-to-earnings ratio is 79.62x while First Physicians Capital Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint Corp. (United States) is 2.57x versus 1.42x for First Physicians Capital Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

UNIVEC has a net margin of 2.17% compared to The Joint Corp. (United States)'s net margin of --. The Joint Corp. (United States)'s return on equity of -1.38% beat UNIVEC's return on equity of --.

The Joint Corp. (United States) has a consensus price target of $10.67, signalling upside risk potential of 16.2%. On the other hand UNIVEC has an analysts' consensus of -- which suggests that it could fall by --. Given that The Joint Corp. (United States) has higher upside potential than UNIVEC, analysts believe The Joint Corp. (United States) is more attractive than UNIVEC.

The Joint Corp. (United States) has a beta of 1.349, which suggesting that the stock is 34.866% more volatile than S&P 500. In comparison UNIVEC has a beta of -0.101, suggesting its less volatile than the S&P 500 by 110.112%.

The Joint Corp. (United States) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UNIVEC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint Corp. (United States) pays -- of its earnings as a dividend. UNIVEC pays out -- of its earnings as a dividend.

The Joint Corp. (United States) quarterly revenues are $13.4M, which are larger than UNIVEC quarterly revenues of --. The Joint Corp. (United States)'s net income of $290.4K is higher than UNIVEC's net income of --. Notably, The Joint Corp. (United States)'s price-to-earnings ratio is 79.62x while UNIVEC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint Corp. (United States) is 2.57x versus -- for UNIVEC. Usually stocks with elevated PS ratios are considered overvalued.